On the basis of the clinical and laboratory findings, the child was diagnosed as having Guillain-Barré syndrome. Supportive treatment included mechanical ventilation, nasogastric tube feeding ...

Disclosures BMC Neurol. 2013;13 (95) Abstract Background Guillain-Barre syndrome (GBS) is characterized by acute onset and progressive course, and is usually associated with a good prognosis.

GBS is a neuromuscular emergency and rare autoimmune disease that affects at least 150,000 people worldwide each year, with no FDA-approved therapies. In its acute phase, GBS rapidly progresses toward ...

Annexon, Inc. Presents Positive Real-World Evidence for Tanruprubart in Guillain-Barré Syndrome at 2025 PNS Annual Meeting May 19, 2025 — 04:13 pm EDT Written by None for Quiver Quantitative -> ...

First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of ...

About Guillain-Barré Syndrome (GBS) GBS is a rare neuromuscular emergency resulting from an acute autoantibody and classical complement-mediated attack on peripheral nerves that generally occurs ...

First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) ...

First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005 ...

Source Reference: Allen J, et al "GBS-02: A phase 3 study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of ANX005 in patients with Guillain-Barré syndrome (GBS)" AAN 2025.

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another effort to improve treatment of the rare condition. | As it advances a ...

About Guillain-Barré Syndrome GBS is a rare neuromuscular emergency resulting from an acute autoantibody and classical complement-mediated attack on peripheral nerves that generally occurs ...

Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease ...